The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Seikagaku, Ferring Finalize Licensing Deal for Lumbar Disc Herniation Drug
August 30, 2016
- Nichi-Iko Completes Tender Offer for Sagent
August 30, 2016
- Shionogi’s Sakigake-Designated Flu Med Shows Efficacy in Japan PII
August 30, 2016
- Hisamitsu’s NSAIDs Patch Disappoints in Japan PII/III
August 30, 2016
- Mylan, Pfizer Recalling 2 Generic Products in Japan
August 29, 2016
- Vimpat Filed for Monotherapy Approval in Japan: Daiichi Sankyo, UCB
August 29, 2016
- Sizzling DOAC Market - 4: Companies Aim to Differentiate Their Products through Quality of Information
August 29, 2016
- CSL Behring Seeks Approval of Human Prothrombin Complex
August 26, 2016
- Actemra Filed for Weekly Dosage for Inadequately Controlled RA
August 26, 2016
- Mitsubishi Tanabe Transitions from “Open Innovation” to “Open Shared” System: President
August 26, 2016
- Sizzling DOAC Market - 3: Dosage and Administration Vary by Product for PE/DVT Treatment
August 26, 2016
- Sizzling DOAC Market - 2: Makers Accumulating Data from Actual Clinical Settings to Support Proper Use
August 25, 2016
- Announcement: Real World Data Japan 2016 to Be Held at Westin Tokyo Hotel on October 18-19
August 25, 2016
- Sizzling DOAC Market - 1: Japan Sales Reaching 140 Billion Yen on 4-Way Fight
August 24, 2016
- Canaglu-Tenelia Combo Filed in Japan: Mitsubishi Tanabe
August 23, 2016
- GSK Paid 6.2 Billion Yen to Doctors, Medical Institutions in 2015
August 23, 2016
- New Treatment Options Arriving in Multiple Myeloma Arena
August 23, 2016
- Sales per Drug Rep Check in at 168 Million Yen in FY2015: Survey
August 22, 2016
- Oncolys to Set Up US Subsidiary to Ratchet Up Licensing Activities
August 22, 2016
- Evidence for Actair Sublingual Tablets “Sets It Apart from Other Therapies”: Shionogi
August 22, 2016
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…